All In Biotech

Drug Trial Radar · NCT01363323

Effect of Methylnaltrexone (MNTX) on Electrocardiogram (ECG) Parameters and Cardiac Repolarization

A Randomized, Double-Blind, Placebo/Positive Controlled, Evaluation of the Effects of MNTX on ECG Parameters and Cardiac Repolarization in Normal Volunteers

Last checked: Nov 19, 2026Latest source record: Nov 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 546 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

546

Actual

Start

Nov 2004

Primary completion

Jan 2005

Study completion Feb 2005

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Jun 1, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will employ a single-center, randomized, double-blind parallel-group design for MNTX and placebo, with a positive control (moxifloxacin) dosed single-blind to confirm methodology, in normal healthy male and female volunteers. Multiple ECGs will be obtained after single clinical and supratherapeutic doses of MNTX to assess ECG effects compared to placebo.

Conditions

  • Healthy Volunteers

Interventions

  • Methylnaltrexone (MNTX)Drug

    Dose 1

  • Methylnaltrexone (MNTX)Drug

    Dose 2

  • Methylnaltrexone (MNTX)Drug

    Dose 3

  • PlaceboDrug

  • MoxifloxacinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Effects of MNTX on QTcI durationTime frame: 3 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Progenics Pharmaceuticals

    Tarrytown, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.